Medicine
Latanoprostene bunod 0.24 mg/mL eye drops
Latanoprostene bunod 0.24 mg/mL eye drops is a generic prescription medicine for ophthalmic use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Unopened bottle should be stored refrigerated at 2º to 8ºC (36º to 46ºF)…
Key facts
- Active ingredient (INN)
- Latanoprostene bunod
- Brand
- Sold under the generic name
- Strength
- 0.24 mg/mL
- Dosage form
- Eye drops
- Route
- Ophthalmic
- Packs
- 1 bottle
- Manufacturer
- Gland PharmaIndia
- Origin register
- US FDA, United States
- Storage
- Unopened bottle should be stored refrigerated at 2º to 8ºC (36º to 46ºF). Protect from freezing. Once a bottle is opened it may be stored at 2º to 25ºC (36º to 77ºF) for 8 weeks. During shipment, bottles may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 14 days. Protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 April 2025
- Identifiers
- RxCUI 1988394DailyMed set ID 1beedfbd-5e2b-4ab1-ab8e-8320e69af1eaNDC 68083-563, 68083-564Application ANDA217387
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 2.5 mL in 1 bottle | 68083-563-01 | Gland PharmaIndia | 29 April 2025 |
| 1 bottle in 1 carton / 5 mL in 1 bottle | 68083-564-01 | Gland PharmaIndia | 29 April 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 2 November 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Latanoprostene bunod 0.24 mg/mL eye drops.
Clinical summary
Latanoprostene bunod is a prescription medicine indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is available as eye drops for ophthalmic use. MedsAcross supplies Latanoprostene bunod for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Latanoprostene bunodFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Vyzulta prescribing information (Bausch & Lomb) · U.S. National Library of Medicine, DailyMed
Need Latanoprostene bunod 0.24 mg/mL eye drops for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.